Free Trial

Digirad (DRAD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
61,911 shs
Average Volume
485,592 shs
Market Capitalization
$4.24 million
P/E Ratio
Dividend Yield
Price Target
DRAD stock logo

About Digirad Stock (NASDAQ:DRAD)

Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. It also develops, sells, and maintains solid-state gamma cameras, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages real estate assets and investments. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.

DRAD Stock News Headlines

Rock icon Jeff Beck dead at 78
Star Equity Holdings, Inc. Iss -
See More Headlines
Receive DRAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Digirad and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Electromedical Equipment
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$114.18 million
Cash Flow
$1.29 per share
Book Value
$10.30 per share


Free Float
Market Cap
$4.24 million
Not Optionable
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Matthew Gabel Molchan (Age 53)
    Pres, CEO & Director
    Comp: $705.96k
  • Mr. David James Noble (Age 50)
    CFO & COO
    Comp: $495.77k
  • Mr. Martin B. Shirley (Age 58)
    Pres of Digirad Imaging Solutions
    Comp: $427.94k
  • Ms. Hannah Bible
    VP of Legal & Fin.
  • Mr. Bob Halbert
    Sr. Director of Human Resource

DRAD Stock Analysis - Frequently Asked Questions

How were Digirad's earnings last quarter?

Digirad Co. (NASDAQ:DRAD) posted its earnings results on Wednesday, November, 18th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by $0.34. The medical equipment provider earned $30.35 million during the quarter. Digirad had a negative net margin of 5.32% and a negative trailing twelve-month return on equity of 3.75%.

Is Digirad a good dividend stock?

Digirad (NASDAQ:DRAD) pays an annual dividend of $2.20 per share and currently has a dividend yield of 83.65%. DRAD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for DRAD.

When did Digirad's stock split?

Shares of Digirad reverse split on the morning of Wednesday, June 5th 2019. The 1-10 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 4th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Matt Molchan's approval rating as Digirad's CEO?

26 employees have rated Digirad Chief Executive Officer Matt Molchan on Matt Molchan has an approval rating of 70% among the company's employees. 57.0% of employees surveyed would recommend working at Digirad to a friend.

What other stocks do shareholders of Digirad own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Digirad investors own include Gilead Sciences (GILD), AT&T (T), Exelixis (EXEL), Enphase Energy (ENPH), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), AcelRx Pharmaceuticals (ACRX), Amyris (AMRS), General Electric (GE) and Genocea Biosciences (GNCA).

This page (NASDAQ:DRAD) was last updated on 5/23/2024 by Staff

From Our Partners